8-KEarnings & ResultsExhibits & Filings

ELI LILLY & Co 8-K Report, Financial Results (Jan 29, 2013)

Filed January 29, 2013For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on January 29, 2013, to report its financial results for the fourth quarter and full year ended December 31, 2012. The filing includes a press release detailing these results and was accompanied by a teleconference for analysts and media. A key aspect of the report is Lilly's use of non-GAAP financial measures, such as non-GAAP net income and earnings per share, which the company believes offer valuable insights into ongoing operations and aid in period-over-period comparisons by excluding highly variable and unpredictable items. While the 8-K itself is a routine filing for earnings announcements, investors should pay close attention to the specific figures released in the accompanying press release (Exhibit 99) for detailed performance metrics. The company emphasizes that these non-GAAP measures are supplementary to GAAP figures and are used internally for performance evaluation and resource allocation. Prospective earnings guidance provided by the company is also subject to adjustments for similar unpredictable future matters.

Key Highlights

  • 1Eli Lilly & Co. reported its Q4 and full-year 2012 financial results via an 8-K filing on January 29, 2013.
  • 2The report confirms the issuance of a press release and a teleconference held to discuss the Q4 and full-year 2012 financial performance.
  • 3Lilly utilizes non-GAAP financial measures (e.g., non-GAAP net income, EPS) in its reporting.
  • 4The company asserts that non-GAAP measures provide useful insights into ongoing operations and facilitate meaningful period-over-period comparisons.
  • 5Items excluded in non-GAAP calculations are typically highly variable, difficult to predict, and can significantly impact reported operations.
  • 6Management uses non-GAAP measures internally for business performance evaluation, resource allocation, and incentive compensation assessment.
  • 7Investors are advised to consider non-GAAP measures in addition to, not as a substitute for, GAAP financial performance.

Frequently Asked Questions

This 8-K filing serves to report Eli Lilly & Company's financial results for the fourth quarter and the full fiscal year ended December 31, 2012. It formally announces the earnings release and any associated analyst calls or webcasts.

Non-GAAP financial measures are financial performance metrics that exclude certain items that may not be indicative of ongoing operational performance. Lilly uses them, such as non-GAAP net income and earnings per share, because they believe these measures provide a clearer view of the company's underlying business performance by removing volatile or unpredictable items, aiding in trend analysis and comparisons.

Investors should view non-GAAP measures as supplemental information to, not a replacement for, the company's financial results prepared in accordance with Generally Accepted Accounting Principles (GAAP). Lilly's filing explicitly states that these non-GAAP figures are intended to help evaluate ongoing operations and identify trends that might otherwise be obscured by GAAP reporting.

The detailed financial results, including the press release and related financial statements, are attached to this 8-K filing as Exhibit 99. This exhibit is the primary source for the specific Q4 and full-year 2012 performance data and the reconciliation between GAAP and non-GAAP figures.